PLEN-3 - COVID-19 Vaccines: Timely Global Real-World Evidence
8:30 AM – 10:00 AM US Eastern Time
PLEN-3 - COVID-19 Vaccines: Timely Global Real-world Evidence
Location: PLEN-3
Vaccines
Concurrent Session 4
10:00 AM – 11:30 AM US Eastern Time
CW12 - Concurrent Workshops 5
10:00 AM – 11:30 AM US Eastern Time
WS-12 - Pediatric Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV 2) and Potential Health Consequences (submitted on Behalf of the ISPE RWE covid-19 Workgroup)
Location: WS-12
Disease Epidemiology/Clinical Course
10:00 AM – 11:30 AM US Eastern Time
WS-14 - Product Surveillance and Signal Management: Now Is the Time for Methodologist Engagement!
Location: WS-14
Medical Devices
10:00 AM – 11:30 AM US Eastern Time
WS-16 - RWE Blueprints: Decoding SPACE, SPIFD, Start-rwe, and Other Tools Promoting Principled Pharmacoepidemiology
Location: WS-16
Methods in Pharmacoepidemiology
10:00 AM – 11:30 AM US Eastern Time
WS-17 - Selection Matters: Addressing Biases in Linked Clinico-genomic Data Sets
Location: WS-17
Methods in Pharmacoepidemiology
10:00 AM – 11:30 AM US Eastern Time
WS-18 - Strategies for the Use of Real-world Data to Conduct covid-19-related Pharmacoepidemiology
Location: WS-18
Methods in Pharmacoepidemiology
Oral Presentations Session 4
11:45 AM – 1:30 PM US Eastern Time
OP-02 - Brains or Bytes? In Search of Patterns
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Brains or Bytes? In Search of Patterns
Location: OP-02
11:45 AM – 1:30 PM US Eastern Time
OP-2A - Identifying Active Pregnancies Using ICD-10 Z3A Codes versus Completed Pregnancies Using Outcomes
Location: OP-02
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-2B - Prediction Algorithm for Identifying Patients with Fabry or Pompe Disease in Electronic Health Records
Location: OP-02
Rare Disease
11:45 AM – 1:30 PM US Eastern Time
OP-2C - The Impact of Longitudinal Data-completeness of Electronic Health Record (EHR) Data on Prognostic Risk Score Misclassification
Location: OP-02
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-2D - Leveraging Artificial Intelligence (AI) Technologies for Automated Identification of Total Knee Arthroplasty (TKA) Devices in Electronic Health Records
Location: OP-02
Medical Devices
11:45 AM – 1:30 PM US Eastern Time
OP-2E - Improving Methods of Identifying Anaphylaxis for Medical Product Safety Surveillance Using Natural Language Processing and Machine Learning
Location: OP-02
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-2F - Validation of an Algorithm to Identify Hormonal Contraceptive Exposure in a Large Integrated Health Care Delivery System Database
Location: OP-02
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-05 - COVID-19 Potpourri: Vaccines, Long Haulers, and the NFL
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: COVID-19 Potpourri: Vaccines, Long Haulers, and the NFL
Location: OP-05
11:45 AM – 1:30 PM US Eastern Time
OP-5A - Descriptive Epidemiology of Adverse Events of Special Interest for COVID-19 Vaccines Across 7 Countries and 4 Continents: A Multinational Network Cohort Study
Location: OP-05
Vaccines
11:45 AM – 1:30 PM US Eastern Time
OP-5B - Population Testing for COVID-19: Can a Rapid Antigen Test Rule out Infection?
Location: OP-05
Medical Devices
11:45 AM – 1:30 PM US Eastern Time
OP-5C - Impact of COVID-19 Social Distance Restrictions on Hospital Encounters Due to Injury by Poisoning or Toxicity of Medications or Non-medicinal Substances
Location: OP-05
Pharmacovigilance
11:45 AM – 1:30 PM US Eastern Time
OP-5D - Persistence of COVID-19 Symptoms 90 Days Post-acute Infection: Insights from a Community-based Registry
Location: OP-05
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-5E - Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized with COVID-19 in the United states:
results from the National COVID Cohort Collaborative (N3C)
Location: OP-05
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-5F - COVID-19 in Children: Treatment Patterns in the Real-world Hospital Setting
Location: OP-05
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-07 - Fast and Furious: Driving Down the Clinical Course of Disease Epidemiology
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Fast and Furious: Driving down the Clinical Course of Disease Epidemiology
Location: OP-07
11:45 AM – 1:30 PM US Eastern Time
OP-7A - Impact of Non-alcoholic Steatohepatitis (NASH) Case Definition on Population Characteristics Identified in a US Claims Database
Location: OP-07
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-7B - The Effect of Epidural Steroid Injections on Fracture Risk Among Medicare Patients
Location: OP-07
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-7C - Persistence of Anticoagulation After Receiving Transcatheter Left Atrial Appendage Occlusion vs. Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Location: OP-07
Medical Devices
11:45 AM – 1:30 PM US Eastern Time
OP-7D - Longitudinal Adherence Trajectories to Biologic Disease Modifying Anti-rheumatic Drugs in Tuscany, Italy
Location: OP-07
Methods in Pharmacoepidemiology
11:45 AM – 1:30 PM US Eastern Time
OP-7E - Hyperthyroidism and Breast Cancer Recurrence and Mortality: A Danish Population-based Cohort Study
Location: OP-07
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-7F - Incidence Rates of Select Outcomes Among Patients with Non-alcoholic Steatohepatitis (NASH) and Evidence of Fibrosis and Cirrhosis
Location: OP-07
Disease Epidemiology/Clinical Course
11:45 AM – 1:30 PM US Eastern Time
OP-10 - Impact of Disparities and Stigma on Drug Access and Utilization
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Impact of Disparities and Stigma on Drug Access and Utilization
Location: OP-10
11:45 AM – 1:30 PM US Eastern Time
OP-10A - Disparities in Hepatitis C Treatment in the Era of Direct-acting Antivirals Among Arizona Medicaid Beneficiaries
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-10B - Sources of Racial/ethnic Disparities in Antidepressant Treatment: Analysis of the Medical Expenditure Panel Survey Data
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-10C - Do Medicare Part D Low-income Subsidies Narrow Disparities in Orally-administered Antimyeloma Therapy Initiation?
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-10D - Impact of Race, Ethnicity, and Sex on Treatment of Non-valvular Atrial Fibrillation
Location: OP-10
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-10E - The Impact of Sex on the Quality of Medication Treatment in Patients with Type 2 Diabetes
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-10F - Changes in Buprenorphine Utilization During the COVID-19 Pandemic in the US
Location: OP-10
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-12 - Look Who's Talking Now: Capturing Patient and Provider Perspectives in Health Data
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Look Who's Talking Now: Capturing Patient and Provider Perspectives in Health Data
Location: OP-12
11:45 AM – 1:30 PM US Eastern Time
OP-12A - Participant Engagement and Adherence in an Arthritispower Real-world Study to Capture Smartwatch and Patient-reported Outcome Data Among Rheumatoid Arthritis Patients
Location: OP-12
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-12B - Ranitidine and Other histamine2-receptor Antagonists – a Rapid Response Drug Utilisation Study Using Electronic Health Care Data from Six European Countries
Location: OP-12
Drug Utilization Research
11:45 AM – 1:30 PM US Eastern Time
OP-12C - The Friends of Cancer Research Real World Data (RWD) Pilot 2.0 Collaboration: Implementation of Standardized Methodological Approaches for Evaluation of Oncology RWD
Location: OP-12
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-12D - Cost-effectiveness of Systematic Treatments for Metastatic Castration-sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-analysis
Location: OP-12
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-12E - Telemedicine Use Among U.S. Patients with Cancer During the COVID-19 Pandemic
Location: OP-12
Health Economics/Outcomes Research
11:45 AM – 1:30 PM US Eastern Time
OP-12F - Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Location: OP-12
Drug Effectiveness
11:45 AM – 1:30 PM US Eastern Time
OP-16 - Pregnancy: Beyond opioids
11:45 AM – 1:30 PM US Eastern Time
Oral Papers: Pregnancy: Beyond Opioids
Location: OP-16
11:45 AM – 1:30 PM US Eastern Time
OP-16A - First Trimester Exposure to Buprenorphine Compared to Methadone for Treatment of Opioid Use Disorders and the Risk of Congenital Malformations
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16B - Characteristics of Initial Postpartum Opioid Prescribing and Risks of Serious Opioid-related Events After Cesarean Delivery
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16C - Prescription Opioid Type and the Risk of Neonatal Opioid Withdrawal Syndrome
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16D - Benzodiazepine Use in the First Trimester and Risk of Congenital Malformations: A Nationwide Cohort Study in South Korea
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16E - Comparative Safety of In-utero Exposure to Buprenorphine Combined with Naloxone versus Buprenorphine Monoproduct with Respect to Congenital Malformations
Location: OP-16
Pregnancy and Lactation
11:45 AM – 1:30 PM US Eastern Time
OP-16F - Prenatal Analgesic Opioid Exposure and Risk of ADHD in Childhood
Location: OP-16
Pregnancy and Lactation
Annual Members Meeting/Awards Ceremony
1:45 PM – 2:45 PM US Eastern Time
MBMT - Annual Members Meeting/Awards Ceremony
1:45 PM – 2:45 PM US Eastern Time
Annual Members Meeting/awards Ceremony
Location: MBMT
Oral Presentations Session 5
3:00 PM – 4:30 PM US Eastern Time
OP-08 - From Patient to Policy Impact: Benefit-Risk Assessment, Communication, and Evaluation (BRACE) SIG
3:00 PM – 4:30 PM US Eastern Time
Oral Papers: From Patient to Policy Impact: Benefit-risk Assessment, Communication, and Evaluation (BRACE) SIG
Location: OP-08
3:00 PM – 4:30 PM US Eastern Time
OP-8A - Impact of Fda’s Regulatory Actions on the Quality of REMS Survey Methodology Protocols (2007 – 2020)
Location: OP-08
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:00 PM – 4:30 PM US Eastern Time
OP-8B - Influence of Drug Safety Advisories on Drug Utilization: An International Interrupted Time Series and Meta-analysis Study
Location: OP-08
Drug Utilization Research
3:00 PM – 4:30 PM US Eastern Time
OP-8C - Preferences Concerning Drug Safety Communication of Hospital-based Specialist in the Netherlands
Location: OP-08
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:00 PM – 4:30 PM US Eastern Time
OP-8D - Regulatory Approval of Phentermine/topiramate for Obesity Management and Off-label Use of Topiramate: A Fairytale for Drug Repurposing and a Maze for Risk Mitigation
Location: OP-08
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:00 PM – 4:30 PM US Eastern Time
OP-8E - What Matters to Patients When Considering Treatments for Prevention of Rheumatoid Arthritis: A Preference Study in the United Kingdom, Germany, and Romania
Location: OP-08
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:00 PM – 4:30 PM US Eastern Time
OP-13 - MedTech Globetrotting - Assisting Medical Devises Effects in the Real World
3:00 PM – 4:30 PM US Eastern Time
Oral Papers: Medtech Globetrotting - Assisting Medical Devises Effects in the Real World
Location: OP-13
3:00 PM – 4:30 PM US Eastern Time
OP-13A - Real-world Epidemiologic and Genetic Evidence Synthesis Reveals the Sex-dependent Role of GNAS Snps in Hip Arthroplasty Related Periprosthetic Osteolysis
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13B - The Association Between Bariatric Surgery and Carpal Tunnel Syndrome: A Cohort Study from Swedish Nationwide Healthcare Registries
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13C - Comparison of 10- and 15-year Outcomes of Bioprosthetic and Mechanical Aortic Valve Replacement in Patients Aged Under 65 Years: Australian Study Using Linked Data for 4,704 Patients
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13D - Sex-differences in Risk of Early Revision After Primary Total Knee Arthroplasty
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13E - The Association Between Bariatric Surgery and Cataract: A Cohort Study from Swedish Nationwide Healthcare Registries
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-13F - Comparative Patient Characteristics of Transcatheter Left Atrial Appendage Occlusion vs. Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Location: OP-13
Medical Devices
3:00 PM – 4:30 PM US Eastern Time
OP-21 - Psychotropics: Bitter Pills to Swallow in Pregnancy
3:00 PM – 4:30 PM US Eastern Time
Oral Papers: Psychotropics: Bitter Pills to Swallow in Pregnancy
Location: OP-21
3:00 PM – 4:30 PM US Eastern Time
OP-21A - Prenatal Antiseizure Medication Exposure and Risk of Autism and Intellectual Disability. SCAN-AED: A Nordic Cohort Study
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
OP-21B - The Comparative Safety of Antiseizure Medication Polytherapy versus Valproate in Pregnancy and Risk of Major Congenital Malformations
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
OP-21C - Antidepressant Use During Pregnancy and the Risk of Neurodevelopmental Disorders in Children
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
OP-21D - The Impact of In-utero Antipsychotic Drug Exposure on Congenital Malformations: An International Cohort Study
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
OP-21F - The Impact of In-utero Antipsychotic Exposure on Neurodevelopmental Disorders in Children
Location: OP-21
Pregnancy and Lactation
3:00 PM – 4:30 PM US Eastern Time
PP-01 - Potpourri
3:00 PM – 4:30 PM US Eastern Time
PP-01 - Oral Presentations Potpourri
Location: PP-01
3:00 PM – 4:30 PM US Eastern Time
PP-01A - Approach to Falsify Calendar Time Instrumental Variable Assumptions in Estimating Treatment Effects
Location: PP-01
3:00 PM – 4:30 PM US Eastern Time
PP-01B - Risk of Fall-related Injury Associated with Concomitant Use of Prescription Opioids and Gabapentinoids Among Older Adults with Chronic Noncancer Pain
Location: PP-01
3:00 PM – 4:30 PM US Eastern Time
PP-01C - Ethnic Differences in COVID-19 Infection, Hospitalisation, and Mortality: An Opensafely Analysis of 17 Million Adults in England
Location: PP-01
Disease Epidemiology/Clinical Course
3:00 PM – 4:30 PM US Eastern Time
PP-01D - Nondifferential Treatment Misclassification Biases Toward the Null? Not a Safe Bet
Location: PP-01
Drug Utilization Research
3:00 PM – 4:30 PM US Eastern Time
PP-01E - Multi-depth, Iterative Causal Forest for Subgroup Identification
Location: PP-01
Disease Epidemiology/Clinical Course
3:00 PM – 4:30 PM US Eastern Time
PP-01F - Predictors of Severe COVID-19 Outcome in Patients with Rheumatoid Arthritis
Location: PP-01
Pharmacovigilance
Oral Presentations Session 6
4:30 PM – 6:00 PM US Eastern Time
OP-01 - Application of Pharmacoepidemiologic Study Designs for Research Across the Cancer Continuum
4:30 PM – 6:00 PM US Eastern Time
Oral Papers: Application of Pharmacoepidemiologic Study Designs for Research Across the Cancer Continuum
Location: OP-01
4:30 PM – 6:00 PM US Eastern Time
OP-1A - Proton Pump Inhibitors and Risk of Gastric Cancer: A Population-based Cohort Study
Location: OP-01
Safety End Points
4:30 PM – 6:00 PM US Eastern Time
OP-1B - Efficacy and Safety of Treatments for Nonmetastatic Castration-resistant Prostate Cancer: A Matching-adjusted Indirect Comparison and Network Meta-analysis
Location: OP-01
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-1C - Comparative Safety of Conjugated Estrogens/bazedoxifene (CE/BZA) versus Estrogen/progestin Combination Hormone Therapy (EP): A Multi-database Cohort Study
Location: OP-01
Safety End Points
4:30 PM – 6:00 PM US Eastern Time
OP-1D - Risk of Malignancies in Newly Treated Patients with Disease-modifying Drugs for Multiple Sclerosis: Assessment According to Cohort and Nested-case Control Approaches
Location: OP-01
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-1E - Vitamin K Antagonists and Risk of Myelodysplastic Syndrome: A Nationwide Cohort Study in Atrial Fibrillation Patients
Location: OP-01
Safety End Points
4:30 PM – 6:00 PM US Eastern Time
OP-1F - Use of Proton Pump Inhibitors and Risk of Pancreatic Adenocarcinoma: A Case-control Study Based on the French National Health Data System (SNDS)
Location: OP-01
Safety End Points
4:30 PM – 6:00 PM US Eastern Time
OP-11 - Just How Well Does it Work in Real Life?
4:30 PM – 6:00 PM US Eastern Time
Oral Papers: Just How Well Does It Work in Real Life?
Location: OP-11
4:30 PM – 6:00 PM US Eastern Time
OP-11A - Calibrating Real-world Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Inflammatory Bowel Disease
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11B - Shorter Drug Holiday After 3 or More Years of Risedronate versus Alendronate Is Important to Maintain Osteoporotic Fracture Protection
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11C - Cardiovascular Effectiveness of SGLT-2 Inhibitors versus Metformin as First-line Treatment for Type 2 Diabetes
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11D - Effect of SGLT-2 Inhibitors on Egfr in Type 2 Diabetes with Different Baseline Renal Functions: A Multi-center Study
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11E - Comparative Effectiveness of Empagliflozin in Reducing Total Cardiovascular Events in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-11F - Initiation of Sodium‐glucose Co‐transporter 2 Inhibitors and Progression of Renal Disease Among Patients with type-2 Diabetes: A Population-based Cohort Study
Location: OP-11
Drug Effectiveness
4:30 PM – 6:00 PM US Eastern Time
OP-17 - Pregnancy: Diabetes and a surprise
4:30 PM – 6:00 PM US Eastern Time
Oral Papers: Pregnancy: Diabetes and a Surprise
Location: OP-17
4:30 PM – 6:00 PM US Eastern Time
OP-17A - Characteristics and Outcomes of Pregnancies in Women with Heart Failure: A Retrospective Cohort Study in the Sentinel System
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17B - Metformin and Risk of Adverse Pregnancy Outcomes Among Pregnant Women with Gestation Diabetes in the United Kingdom: A Population-based Cohort Study
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17C - The Role of Propensity Score Matching in Claims-based Studies for Achieving Comparability in hba1c Levels Between Treatments in Pregnant Women with Type 2 Diabetes
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17D - Balance of Unmeasured Covariates After Propensity Score Matching Based on Measurable Covariates in Perinatal Pharmacoepidemiologic Studies
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17E - Development and Validation of ICD-10 Claims-based Algorithms for Pregnancy and Infant Outcomes
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-17F - Metformin versus Insulin in Early Pregnancy and Risk of Congenital Malformations
Location: OP-17
Pregnancy and Lactation
4:30 PM – 6:00 PM US Eastern Time
OP-20 - PS I love you, XXII
4:30 PM – 6:00 PM US Eastern Time
Oral Papers: PS I Love You, XXII
Location: OP-20
4:30 PM – 6:00 PM US Eastern Time
OP-20A - Evaluating When Effect Estimates Change After Propensity Score Trimming Because of Differing Effect Measure Modifier Distributions
Location: OP-20
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-20B - Optimization-based Stable Balancing Weights vs. Generalized Boosted Modeling for Propensity Score Weighting
Location: OP-20
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-20C - Controlling for Differential Regression to the Mean Using Summary Measures of Pre-treatment Laboratory Values in Propensity Scores
Location: OP-20
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-20D - An Evaluation of Direct and Propensity Score Matching versus Propensity Score Stratification for Confounding Adjustment in Primary Total Hip Arthroplasty
Location: OP-20
Medical Devices
4:30 PM – 6:00 PM US Eastern Time
OP-20E - Disease Risk Score as Alternative to Propensity Score Under Multiple Confounders and High Prevalence of Outcome: A Simulation Study Motivated by the Emergence of Multiple Repurposed Medicines During the COVID-19 Pandemic
Location: OP-20
Methods in Pharmacoepidemiology
4:30 PM – 6:00 PM US Eastern Time
OP-20F - Cardinality Matching vs Propensity Score Matching in Multiple Sclerosis
Location: OP-20
Methods in Pharmacoepidemiology
Plenary 3- Repeat
8:00 PM – 9:30 PM US Eastern Time
PLEN-3B - REPEAT: COVID-19 Vaccines: Timely Global Real-World Evidence
8:00 PM – 9:30 PM US Eastern Time
PLEN-3B - REPEAT: COVID-19 Vaccines: Timely Global Real-world Evidence
